Ann: Trading Halt, page-39

Usually I disagree with you on your view on Kazia.
However one of my other stocks (also BIO) dropped like a stone when they announced a license for the US area only. I believe the consensus was too small an upfront payment, only US$10M, even the “packaged deal” was worth circa US$450M, since all cost for the phase 3 trial will be paid for, and any data generated from the trial could be used for other regional license negotiations.
Even today this stock is 50% down from when the original deal was announced.
I sincerely hoped that this is not going to happen here, but I am worried. I have a lot riding in KZA.